Substantially Advancing Clinical Outcomes & Economic Impact of RefluxStop®

The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to be held on Wednesday, June 10, 2026, at 14:00 at Hotel Kommod, Industriering 14, 9491 Ruggell, Liechtenstein.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop® for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces a new RefluxStop® study showing the next-gen surgical solution for GERD is highly cost-effective compared to current standard of GERD care in the Italian healthcare system.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that it has submitted its final response to the U.S. Food and Drug Administration (FDA) feedback regarding Module 3 of the Premarket Approval (PMA) application for RefluxStop®.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces breakthrough long-term data from Inselspital in Bern, the largest university hospital in Switzerland, demonstrating excellent safety and efficacy in complex patients, including aperistalsis and lung transplant recipients.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces great interest in the RefluxStop® procedure’s unique mechanism of action and excellent clinical outcomes at Digestive Disease Week (DDW) 2026 in Chicago.

Implantica AG (publ) invites investors to a presentation of the first quarter 2026 at 15:00 CET on May 22. The interim report for the first quarter (Q1 2026) will be published at 8:00 a.m. CET on the same day.

Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2025. The annual report is now available on the company’s website.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux – a condition affecting over 1 billion people worldwide – announces the publication of the largest and first-of-its-kind real-world safety outcomes study of RefluxStop®. The study demonstrating excellent long-term results has been published in Scientific Reports, part of the prestigious Nature portfolio of journals.

RefluxStop® US Launch Coming Closer, pending FDA approval